Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?

Nephron - Clinical Practice

Volumn 118, Issue 4, 2011, Pages

  Onuigbo, Macaulay A C ^a,b  

^a ALBERT LEA EYE CLINIC   (United States)

^b Mayo Health System   (United States)

Author keywords

Acute kidney injury; Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Chronic kidney disease; End stage renal disease; Late onset renal failure from angiotensin blockade; Renoprevention; Renoprotection; Syndrome of rapid onset end stage renal disease

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL;

ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG SAFETY; DRUG UTILIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 79952324464     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000324164     Document Type: Review

References (139)

1. Canadian Institute for Health Information: Treatment of End-Stage Organ Failure in Canada, 1999 to 2008 -CORR 2010 Annual Report. Ottawa, CIHI, 2010.
2. Stewart JH, McCredie MR, Williams SM, Jager KJ, Trpeski L, McDonald SP, ESRD Incidence Study Group: Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology (Carlton) 2007; 12: 520-527. (Pubitemid 47366645)
3. Imai E, Horio M, Iseki K, et al: Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007; 11: 156-163. (Pubitemid 47012510)
4. Chiu YL, Chien KL, Lin SL, Chen YM, Tsai TJ, Wu KD: Outcomes of stage 3-5 chronic kidney disease before end-stage renal disease at a single center in Taiwan. Nephron Clin Pract 2008; 109:c109-c118.
5. Afifi A, El Setouhy M, El Sharkawy M, et al: Diabetic nephropathy as a cause of end-stage renal disease in Egypt: A six-year study. East Mediterr Health J 2004; 10: 620-626. (Pubitemid 41723447)
6. Collins AJ, Foley RN, Herzog C, et al: United States Renal Data System 2008 annual data report. Am J Kidney Dis 2009; 53(suppl):S1-S374.
7. Hsu CY, Vittinghoff E, Lin F, Shlipak MG: The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141: 95-101.
8. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH: Epidemic of endstage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int 2005; 67: 1684-1691. (Pubitemid 40577702)
9. Ursea N, Mircescu G, Constantinovici N, Verzan C: Nephrology and renal replacement therapy in Romania. Nephrol Dial Transplant 1997; 12: 684-690. (Pubitemid 27170420)
10. Perico N, Plata R, Anabaya A, Codreanu I, Schieppati A, Ruggenenti P, Remuzzi G: Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. Kidney Int Suppl 2005; 97:S87-S94.
11. Liu WJ, Hooi LS: Patients with end stage renal disease: A registry at Sultanah Aminah Hospital, Johor Bahru, Malaysia. Med J Malaysia 2007; 62: 197-200. (Pubitemid 47401507)
12. Hada R, Khakurel S, Agrawal RK, Kafle RK, Bajracharya SB, Raut KB: Incidence of end stage renal disease on renal replacement therapy in Nepal. Kathmandu Univ Med J 2009; 7: 301-305.
13. Ayodele OE, Alebiosu CO: Burden of chronic kidney disease: An international perspective. Adv Chronic Kidney Dis 2010; 17: 215-224.
14. Abraham G, Jayaseelan T, Matthew M, Padma P, Saravanan AK, Lesley N, Reddy YN, Saravanan S, Reddy YN: Resource settings have a major influence on the outcome of maintenance hemodialysis patients in South India. Hemodial Int 2010; 14: 211-217.
15. Ulasi II, Ijoma CK: The enormity of chronic kidney disease in Nigeria: The situation in a teaching hospital in South-East Nigeria. J Trop Med 2010; 2010: 501957.
16. Jha V: End-stage renal care in developing countries: The India experience. Ren Fail 2004; 26: 201-208. (Pubitemid 39050658)
17. Badmus TA, Arogundade FA, Sanusi AA, Akinsola WA, Adesunkanmi AR, Agbakwuru AO, Salako AB, Faponle AF, Oyebamiji EO, Adetiloye VA, Famurewa OC, Oladimeji BY, Fatoye FO: Kidney transplantation in a developing economy: Challenges and initial report of three cases at Ile Ife. Cent Afr J Med 2005; 51: 102-106.
18. Farrington K, Hodsman A, Casula A, Ansell D, Feehally J: UK Renal Registry 11th annual report (December 2008). 4. ESRD prevalent rates in 2007 in the UK: National and centrespecific analyses. Nephron Clin Pract 2009; 111(suppl 1):c43-c68.
19. US Renal Data System: USRDS 2010 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010. http:// www.usrds.org/2010/ADR-booklet-2010-lowres.pdf, http://www.usrds.org/2009/pdf/ V2+02+INC-PREV-09.PDF (accessed December 20, 2010).
20. Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS: Community-based incidence of acute renal failure. Kidney Int 2007; 72: 208-212. (Pubitemid 47067390)
21. Eachempati SR, Wang JC, Hydo LJ, Shou J, Barie PS: Acute renal failure in critically ill surgical patients: Persistent lethality despite new modes of renal replacement therapy. J Trauma 2007; 63: 987-993. (Pubitemid 350098514)
22. Centers for Disease Control and Prevention (CDC): Prevalence of chronic kidney disease and associated risk factors -United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 161-165.
23. Naicker S: End-stage renal disease in sub-Saharan Africa. Ethn Dis 2009; 19(suppl 1):13-15.
24. Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO, Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO: Diseases causing chronic renal failure in Nigerians -a prospective study of 100 cases. Afr J Med Med Sci 1989; 18: 131-137. (Pubitemid 19142054)
25. Adetuyibi A, Akisanya JB, Onadeko BO: Analysis of the causes of death on the medical wards of the University College Hospital, Ibadan, over a 14-year period (1960-1973). Trans R Soc Trop Med Hyg 1976; 70: 466-473. (Pubitemid 8034798)
26. Mircescu G, Capsa D, Covic M, Caprioara MG, Gluhovschi G, Golea O, Ursea N, Gǎrneata L, Cepoi V, Constantinovici N, Covic A: Nephrology and renal replacement therapy in Romania -transition still continues (Cinderella story revisited). Nephrol Dial Transplant 2004; 19: 2971-2980. (Pubitemid 40057617)
27. Nelson CR, Knapp DA: Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension 2000; 36: 600-603.
28. Stafford RS, Monti V, Furberg CD, Ma J: Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension 2006; 48: 213-218. (Pubitemid 44309814)
29. Ma J, Lee KV, Stafford RS: Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006; 48: 846-852. (Pubitemid 44610996)
30. Al Khaja KA, Sequeira RP: Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000. Pharmacoepidemiol Drug Saf 2006; 15: 741-748. (Pubitemid 44649513)
31. McAlister FA, Campbell NR, Duong-Hua M, Chen Z, Tu K: Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade. Diabetes Care 2006; 29: 836-841. (Pubitemid 44115303)
32. Kim KI, Kim Y, Kim HJ, Kang DH, Park JB, Choi DJ, Kim CH, KEY Study Group: Current status and characteristics of hypertension treatment by primary physicians in Korea: Data from Korean epidemiology study on hypertension (KEY study). Am J Hypertens 2008; 21: 884-889.
33. Pillay T, Smith AJ, Hill SR: A comparison of two methods for measuring anti-hypertensive drug use: Concordance of use with South African standard treatment guidelines. Bull World Health Organ 2009; 87: 466-471.
34. Ejeschke E, Ostermann T, Vollmar HC, Kröz M, Bockelbrink A, Witt CM, Willich SN, Matthes H: Valuation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: A prospective observational study. BMC Fam Pract 2009; 10: 78.
35. Olanrewaju TO, Aderibigbe A, Busari OA, Sanya EO: Antihypertensive drug utilization and conformity to guidelines in a sub-Saharan African hypertensive population. Int J Clin Pharmacol Ther 2010; 48: 68-75.
36. Feldstein CA, Garrido D, Chavin JM, Liendo XM, de los Santos AR: Primary care survey of awareness and control of hypertension: A hospital-based study. Am J Ther 2010; 17: 295-300.
37. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM: Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295:F1589-F1600.
38. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20: 489-494.
39. Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, Bleyer AJ, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW: Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol Dial Transplant 2009; 24: 3366-3371.
40. Leak TS, Mychaleckyj JC, Smith SG, Keene KL, Gordon CJ, Hicks PJ, Freedman BI, Bowden DW, Sale MM: Evaluation of a SNP map of 6q24-27 confirms diabetic nephropathy loci and identifies novel associations in type 2 diabetes patients with nephropathy from an African-American population. Hum Genet 2008; 124: 63-71.
41. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
42. Singh DK, Winocour P, Farrington K: Mechanisms of disease: The hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008; 4: 216-226. (Pubitemid 351451302)
43. Goh SY, Cooper ME: Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152. (Pubitemid 351519698)
44. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R: Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166-172. (Pubitemid 38044711)
45. Park S, Bivona BJ, Kobori H, Seth DM, Chappell MC, Lazartigues E, Harrison-Bernard LM: Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol 2010; 298:F37-F48.
46. Matavelli LC, Huang J, Siragy HM: (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol 2010; 37: 277-282.
47. Sasaki H, Kamijo-Ikemori A, Sugaya T, Yamashita K, Yokoyama T, Koike J, Sato T, Yasuda T, Kimura K: Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 2009; 112:c148-c156.
48. Lennon R, Pons D, Sabin MA, Wei C, Shield JP, Coward RJ, Tavare JM, Mathieson PW, Saleem MA, Welsh GI: Saturated fatty acids induce insulin resistance in human podocytes: Implications for diabetic nephropathy. Nephrol Dial Transplant 2009; 24: 3288-3296.
49. An WS, Kim HJ, Cho KH, Vaziri ND: Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol 2009; 297:F895-F903.
50. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J: Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23: 1621-1627. (Pubitemid 351767738)
51. Yamaguchi Y, Iwano M, Suzuki D, Nakatani K, Kimura K, Harada K, Kubo A, Akai Y, Toyoda M, Kanauchi M, Neilson EG, Saito Y: Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54: 653-664.
52. Yokoi H, Mukoyama M, Mori K, Kasahara M, Suganami T, Sawai K, Yoshioka T, Saito Y, Ogawa Y, Kuwabara T, Sugawara A, Nakao K: Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 2008; 73: 446-455. (Pubitemid 351186294)
53. Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW: Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 2008; 93: 1893-1900. (Pubitemid 351656535)
54. Breyer JA: Diabetic nephropathy in insulindependent patients. Am J Kidney Dis 1992; 20: 533-547.
55. Onuigbo MAC: Reno-prevention vs renoprotection: A critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET -a call for more circumspection. QJM 2009; 102: 155-167.
56. Onuigbo MA: Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far? Int J Clin Pract 2010; 64: 1341-1346.
57. Tsalamandris C, Allen TJ, Gilbert RE, et al: Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43: 649-655. (Pubitemid 24138777)
58. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663. (Pubitemid 38392981)
59. Menon V, Wang X, Sarnak MJ, et al: Longterm outcomes in nondiabetic chronic kidney disease. Kidney Int 2008; 73: 1310-1315. (Pubitemid 351693160)
60. Onuigbo MA: The natural history of chronic kidney disease revisited -a 72-month Mayo Health System Hypertension Clinic practice-based research network prospective report on end-stage renal disease and death rates in 100 high-risk chronic kidney disease patients: A call for circumspection. Adv Perit Dial 2009; 25: 85-88.
61. Bansal N, Hsu CY: Long-term outcomes of patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 532-533.
62. Onuigbo MA: Causes of renal failure in patients with type 2 diabetes mellitus. JAMA 2003; 290: 1855, author reply 1855-1856. (Pubitemid 37430600)
63. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259 (erratum published in Lancet 2000; 356: 860).
64. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
65. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
66. Onuigbo M, Weir MR: Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obes Metab 2003; 5: 13-26. (Pubitemid 36367474)
67. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462 (erratum published in N Engl J Med 1993; 330: 152). (Pubitemid 23335891)
68. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364. (Pubitemid 29355751)
69. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
70. Onuigbo MA, Onuigbo NT: Late onset renal failure from angiotensin blockade (LORFFAB): A prospective thirty-month Mayo Health System clinic experience. Med Sci Monit 2005; 11:CR462-CR469. (Pubitemid 41482731)
71. Onuigbo MA, Onuigbo NT: Late-onset renal failure from RAAS blockade. Kidney Int 2006; 70: 1378-1379. (Pubitemid 44435207)
72. Onuigbo MA, Onuigbo NT: Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233-239.
73. Onuigbo MA, Onuigbo NT: Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Ren Fail 2008; 30: 67-72.
74. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. (Pubitemid 351522739)
75. Onuigbo MA, Onuigbo NT: Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: A prospective 50-month Mayo-Health-System clinic analysis. QJM 2008; 101: 519-527. (Pubitemid 351911994)
76. Onuigbo MA, Onuigbo NT: Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: An extended Mayo Clinic prospective 63-month experience. Ren Fail 2008; 30: 363-371. (Pubitemid 351868682)
77. Onuigbo MAC: An analytical review of the evidence-base for reno-protection from the large RAAS blockade trials after ONTARGET. Re-visitation of the potential for iatrogenic renal failure with RAAS blockade? A call for caution. Nephron Clin Pract 2009; 113:c63-c69.
78. Suissa S, Hutchinson T, Brophy JM, Kezouh A: ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
79. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48. (Pubitemid 351688350)
80. Thuraisingham RC, Yaqoob MM: Blood pressure guidelines in chronic kidney disease: A critical review. Nephron Clin Pract 2009; 113:c294-c300.
81. Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
82. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001; 38:e28-e32.
83. Riley RD, Lambert PC, Staessen JA, et al: Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Statist Med 2008; 27; 1870-1893. (Pubitemid 351634244)
84. Ameringer S, Serlin RC, Ward S: Simpson's paradox and experimental research. Nurs Res 2009; 58: 123-127.
85. Cooper H, Patall EA: The relative benefits of meta-analysis conducted with individual participant data versus aggregated data. Psychol Methods 2009; 14: 165-176.
86. Mann JF, Schmieder RE, McQueen M, et al, ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, doubleblind, controlled trial. Lancet 2008; 372: 547-553.
87. Ballermann BJ, Onuigbo MAC: Angiotensins; in Fray JCS (ed): Handbook of Physiology; section 7: The endocrine system, vol III: Endocrine regulation of water and electrolyte balance. New York, Oxford University Press, pp 104-155.
88. Zhang SL, Guo J, Moini B, Ingelfinger JR: Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: Impact on proliferation and apoptosis. Kidney Int 2004; 66: 2181-2192. (Pubitemid 41115281)
89. Chen CO, Park MH, Forbes MS, et al: Angiotensin converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat. Am J Physiol Renal Physiol 2007; 292:F946-F955. (Pubitemid 46393420)
90. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-2274. (Pubitemid 36993311)
91. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. (Pubitemid 351522739)
92. Onuigbo MA, Onuigbo NT: Use of ultrahigh RAAS blockade: Implications for exacerbation of renal failure. Kidney Int 2006; 69: 194-195. (Pubitemid 43117760)
93. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG: Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis 2009; 54: 498-510.
94. Winkelmayer WC, Liu J, Brookhart MA: Altitude and all-cause mortality in incident dialysis patients. JAMA 2009; 301: 508-512.
95. Onuigbo MA: Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients? Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice. Hemodial Int 2009; 13(suppl 1):S24-S29.
96. Onuigbo MA: Radiographic contrast-induced nephropathy and patient mortality. Mayo Clin Proc 2008; 83: 1412-1413.
97. Ahmed AK, Kamath NS, El Kossi M, et al: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2009. DOI: 10.1093/ndt/ gfp511.
98. Onuigbo MA: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010; 25: 1344-1345.
99. Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362(9386):772-776. (Pubitemid 37093917)
100. Pfeffer MA, Swedberg K, Granger CB, et al: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet 2003; 362: 759-766. (Pubitemid 37093915)
101. Rahman M, Pressel S, Davis BR, et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-946. (Pubitemid 40563242)
102. Onuigbo MA: ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169: 1810.
103. Al-Azzam SI, Al-Husein BA, Abu-Dahoud EY, Dawoud TH, Al-Momany EM: Etiologies of acute renal failure in a sample of hospitalized Jordanian patients. Ren Fail 2008; 30: 373-376. (Pubitemid 351868678)
104. Louis BM, Hoch BS, Hernandez C, et al: Protection from the nephrotoxicity of contrast dye. Renal Fail 1996; 18: 639-646. (Pubitemid 26295948)
105. Kini AS, Mitre CA, Kamran M, et al: Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002; 89: 999-1002. (Pubitemid 34310307)
106. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL: The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 2003; 3: 98-103. (Pubitemid 36798317)
107. Cirit M, Toprak O, Yesil M, et al: Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006; 104:c20-c27.
108. Komenda P, Zalunardo N, Burnett S, et al: Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: A case series. Clin Exp Nephrol 2007; 11: 209-213. (Pubitemid 47476789)
109. Gupta RK, Kapoor A, Tewari S, et al: Captopril for prevention of contrast-induced nephropathy in diabetic patients; a randomized study. Indian Heart J 1995; 51: 521-526.
110. Dangas G, Iakovou I, Nikolsky E, et al: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19. (Pubitemid 40051105)
111. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H: Impact of renin-angiotensinaldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: A post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant 2010; 25: 759-764.
112. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, De Vita MV, Michelis MF: The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008; 40: 749-755.
113. Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF: Captopril: Pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol 1984; 17: 243-250. (Pubitemid 14053785)
114. Giudicelli JF, Chaignon M, Richer C, Giroux B, Guedon J: Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. Br J Clin Pharmacol 1984; 18: 749-758. (Pubitemid 15209205)
115. Thakar CV, Kharat V, Blanck S, Leonard AC: Acute kidney injury after gastric bypass surgery. Clin J Am Soc Nephrol 2007; 2: 426-430.
116. Khurana A, McLean L, Atkinson S, Foulks CJ: The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med 2008; 168: 593-597. (Pubitemid 351468394)
117. Russmann S, Lamerato L, Marfatia A, et al: Risk of impaired renal function after colonoscopy: A cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. Am J Gastroenterol 2007; 102: 2655-2663. (Pubitemid 350179356)
118. Arora P, Rajagopalam S, Ranjan R, et al: Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 2008; 3: 1266-1273.
119. Markowitz GS, Nasr SH, Klein P, et al: Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35: 675-684. (Pubitemid 38881077)
120. Rose M, Karlstadt RG, Walker K: Renal failure following bowel cleansing with a sodium phosphate purgative. Nephrol Dial Transplant 2005; 20: 1518-1519. (Pubitemid 41430642)
121. Russmann S, Lamerato L, Marfatia A, et al: Risk of impaired renal function after colonoscopy: A cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. Am J Gastroenterol 2007; 102: 2655-2663. (Pubitemid 350179356)
122. Khurana A, McLean L, Atkinson S, Foulks CJ: The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med 2008; 168: 593-597. (Pubitemid 351468394)
123. Silas Jh, Klenka Z, Solomon SA: Captopril induced reversible renal failure: A marker of renal artery stenosis affecting a solitary kidney. Br Med J (Clin Res Ed) 1983; 286: 1702-1703. (Pubitemid 13094583)
124. Murphy BF, Whitworth JA, Kincaid-Smith P: Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed) 1984; 288: 844-845.
125. Jackson B, McGrath BP, Matthews PG, Wong C, Johnston C: Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 1986; 8: 650-654. (Pubitemid 16044336)
126. Kalra PA, Mamtora H, Holmes AM, Waldek S: Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med 1990; 77: 1013-1018. (Pubitemid 20370992)
127. Devoy MAB, Tomson CR, Edmunds ME, Feehally J, Walls J: Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992; 232: 493-498. (Pubitemid 23024316)
128. Raine AE: Angiotensin-converting enzyme inhibition and renovascular disease. Q J Med 1990; 77: 997-999. (Pubitemid 20370989)
129. Thomas MC: Diuretics, ACE inhibitors and NSAIDs -the triple whammy. Med J Aust 2000; 172: 184-185. (Pubitemid 30131315)
130. Boyd IW, Mathew TH, Thomas MC: Cox-2 inhibitors and renal failure: The triple whammy revisited. Med J Aust 2000; 173: 274.
131. Descombes E, Fellay G: End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency. Ren Fail 2000; 22: 815-821.
132. Thomas MC: Diuretics, ACE inhibitors and NSAIDs -the triple whammy. Med J Aust 2000; 172: 184-185. (Pubitemid 30131315)
133. Loboz KK, Shenfield GM: Drug combinations and impaired renal function -the 'triple whammy'. Br J Clin Pharmacol 2005; 59: 239-243. (Pubitemid 40208862)
134. Raine AE: Angiotensin-converting enzyme inhibition and renovascular disease. Q J Med 1990; 77: 997-999. (Pubitemid 20370989)
135. Jafar TH, Schmid CH, Landa M, et al, ACE Inhibition in Progressive Renal Disease Study Group: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135; 73-87. (Pubitemid 32661190)
136. Jafar TH, Stark PC, Schmid CH, et al, ACE Inhibition in Progressive Renal Disease Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition -a patient-level meta-analysis. Ann Intern Med 2003; 139; 244-252.
137. Kent DM, Jafar TH, Hayward RA, et al, ACE Inhibition in Progressive Renal Disease Study Group: Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18: 1959-1965.
138. Onuigbo MA: Syndrome of rapid-onset end-stage renal disease: A new unrecognized pattern of CKD progression to ESRD. Ren Fail 2010; 32: 954-958.
139. Go AS, Parikh CR, Ikizler TA, Coca S, Siew ED, Chinchilli VM, et al: The Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) study: Design and methods. BMC Nephrol 2010; 11: 22.